Related Experiment Videos
Acquired hemophilia A: a concise review.
Massimo Franchini1, Giorgio Gandini, Tiziana Di Paolantonio
1Servizio di Immunoematologia e Trasfusione--Centro Emofilia, Azienda Ospedaliera di Verona, Italy. mfranchini@mail.univr.it
American Journal of Hematology
|September 3, 2005
Summary
Acquired hemophilia A is a rare autoimmune bleeding disorder caused by antibodies against factor VIII, primarily affecting the elderly. This review covers its epidemiology, diagnosis, clinical features, and treatment advances.
Area of Science:
- Hematology
- Immunology
- Autoimmune Disorders
Background:
- Acquired hemophilia A (AHA) is a rare, severe autoimmune bleeding disorder.
- It is characterized by autoantibodies targeting clotting factor VIII.
- AHA is more prevalent in the elderly population.
Purpose of the Study:
- To provide a comprehensive overview of current knowledge on acquired hemophilia A.
- To analyze the epidemiology, pathogenesis, diagnostic criteria, and clinical manifestations of AHA.
- To discuss advances in managing bleeding episodes and eradicating factor VIII autoantibodies.
Main Methods:
- Literature review of acquired hemophilia A.
- Analysis of epidemiological data.
- Synthesis of current understanding of pathogenesis and clinical features.
- Review of therapeutic strategies for bleeding and autoantibody eradication.
Main Results:
- AHA is a critical condition with significant morbidity and mortality.
- Understanding its association with other conditions is crucial for diagnosis and management.
- Recent therapeutic advances offer improved outcomes for patients.
Conclusions:
- Acquired hemophilia A requires a multidisciplinary approach for optimal patient care.
- Continued research is essential to further improve treatment strategies.
- Early diagnosis and effective management are key to reducing complications.